- Report
- October 2024
- 193 Pages
Global
From €3518EUR$3,545USD£2,919GBP
€3909EUR$3,939USD£3,243GBP
- Report
- August 2024
- 136 Pages
Global
From €2976EUR$2,999USD£2,469GBP
- Report
- December 2024
- 372 Pages
Global
From €5408EUR$5,450USD£4,487GBP
- Report
- May 2024
- 100 Pages
Africa
From €1985EUR$2,000USD£1,647GBP
- Report
- April 2024
- 80 Pages
United States
From €1488EUR$1,500USD£1,235GBP
- Report
- December 2024
- 546 Pages
Global
From €5553EUR$5,596USD£4,607GBP
€6941EUR$6,995USD£5,759GBP
- Report
- October 2024
- 188 Pages
Global
From €3518EUR$3,545USD£2,919GBP
€3909EUR$3,939USD£3,243GBP
- Report
- December 2024
- 89 Pages
Global
From €5557EUR$5,600USD£4,611GBP
- Report
- December 2024
- 158 Pages
Global
From €5408EUR$5,450USD£4,487GBP
- Report
- January 2024
- 200 Pages
Global
From €4962EUR$5,000USD£4,117GBP
- Report
- January 2024
- 200 Pages
Global
From €3969EUR$4,000USD£3,293GBP
- Report
- September 2024
- 187 Pages
Global
From €4465EUR$4,500USD£3,705GBP
- Report
- January 2024
- 182 Pages
Global
From €4465EUR$4,500USD£3,705GBP
- Report
- July 2024
- 150 Pages
Global
From €2977EUR$3,000USD£2,470GBP
€3721EUR$3,750USD£3,087GBP
- Report
- January 2024
- 200 Pages
Global
From €4118EUR$4,150USD£3,417GBP
- Report
- July 2024
- 158 Pages
Global
From €3374EUR$3,400USD£2,799GBP
€4217EUR$4,250USD£3,499GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4962EUR$5,000USD£4,117GBP
- Report
- August 2023
- 1500 Pages
Global
From €8683EUR$8,750USD£7,204GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4962EUR$5,000USD£4,117GBP
- Report
- June 2022
- 55 Pages
India
From €4962EUR$5,000USD£4,117GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more